Abstract
A 1-year-old Japanese female patient with motor retardation was brought to our outpatient clinic by her mother. The child was found to have high serum creatine kinase (CK) level according to the 1-year-old medical checkup and was recommended further evaluation. The girl, the second child in her family, was born at full term in a local hospital and, after birth, was transferred to a general hospital because of muscle hypotonus, poor eye opening and sucking, and a high serum CK level (5461 IU/L: normal ranges are between 40 and 310 IU/L). She was followed up because her doctors considered these symptoms to arise from neonatal asphyxia. The infant developed quickly after 2 weeks, and her serum CK level decreased to normal. She grew up slightly slowly and acquired head control at 5 months of age (commonly acquired at 3–4 months after birth); she could not roll over at 7 months and rehabilitation was started. At 1 year of age, her muscle tonus remained decreased, and her serum CK level was elevated again (7532 IU/L). She could not stand up without support.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Briggs DC, Yoshida-Moriguchi T, Zheng T et al (2016) Structural basis of laminin binding to the LARGE glycans on dystroglycan. Nat Chem Biol 12:810–814
Fukuyama Y, Osawa M, Suzuki H (1981) Congenital progressive muscular dystrophy of the Fukuyama type – clinical, genetic and pathological considerations. Brain and Development 3:1–29
Gerin I, Ury B, Breloy I et al (2016) ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan. Nat Commun 7:11534
Godfrey C, Clement E, Mein R et al (2007) Refining genotype–phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 130:2725–2735
Godfrey C, Foley AR, Clement E et al (2011) Dystroglycanopathies: coming into focus. Curr Opin Genet Dev 21:278–285
Hara Y, Balci-Hayta B, Yoshida-Moriguchi T et al (2011) A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 364:939–946
Hayashi YK, Ogawa M, Tagawa K et al (2001) Selective deficiency of α-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57:115–121
Inamori K, Yoshida-Moriguchi T, Hara Y et al (2012) Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 335:93–96
Kanagawa M, Saito F, Kunz S et al (2004) Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 117:953–964
Kanagawa M, Yu CC, Ito C et al (2013) Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Hum Mol Genet 22:3003–3015
Kanagawa M, Kobayashi K, Tajiri M et al (2016) Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. Cell Rep 14:2209–2223
Kobayashi K, Nakahori Y, Miyake M et al (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394:388–392
Manya H, Chiba A, Yoshida A et al (2004) Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci U S A 101:500–505
Manya H, Yamaguchi Y, Kanagawa M et al (2016) The muscular dystrophy gene TMEM5 encodes a ribitol β1,4-xylosyltransferase required for the functional glycosylation of dystroglycan. J Biol Chem 291:24618–24627
Michele DE, Barresi R, Kanagawa M et al (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418:417–422
Taniguchi-Ikeda M, Kobayashi K, Kanagawa M et al (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478:127–131
Watanabe M, Kobayashi K, Jin F et al (2005) Founder SVA retrotransposal insertion in Fukuyama-type congenital muscular dystrophy and its origin in Japanese and Northeast Asian populations. Am J Med Genet 138A:344–348
Yoshida A, Kobayashi K, Manya H et al (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 1:717–724
Yoshida-Moriguchi T, Campbell KP (2015) Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 25:702–713
Yoshida-Moriguchi T, Willer T, Anderson ME et al (2013) SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341:896–899
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kanagawa, M., Tokuoka, H., Toda, T. (2019). Fukuyama Congenital Muscular Dystrophy and Related Diseases. In: Oohashi, T., Tsukahara, H., Ramirez, F., Barber, C., Otsuka, F. (eds) Human Pathobiochemistry. Springer, Singapore. https://doi.org/10.1007/978-981-13-2977-7_20
Download citation
DOI: https://doi.org/10.1007/978-981-13-2977-7_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-2976-0
Online ISBN: 978-981-13-2977-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)